Enliven Therapeutics Adds Kristine Ball to Board, Expanding Board to Eight Directors
Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, effective October 14, 2026, expanding the board from seven to eight directors. The company says the appointment comes as it prepares to start the pivotal Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026, a routine governance change with no financial results disclosed.
Key points
- Kristine Ball appointed Class II director, term expiring at the 2028 annual meeting, and Audit Committee member, effective October 14, 2026
- Ball receives $45,000 per year as an outside director and $10,000 per year for Audit Committee service
- Initial stock option grant with a grant date fair value of approximately $650,000, vesting monthly over 36 months
- Company plans to initiate the Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.